Is metabotropic glutamate receptor 5 upregulated in prefrontal cortex in fragile X syndrome?

Molecular Autism

Volumn 4, Issue 1, 2013, Pages

  Lohith, Talakad G ^a   Osterweil, Emily K ^b   Fujita, Masahiro ^a   Jenko, Kimberly J ^a   Bear, Mark F ^b   Innis, Robert B ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Fragile X mental retardation protein; Fragile X syndrome; Glutamate receptor; mGluR5; Receptor density; Receptor expression

Indexed keywords

3 METHOXY 5 PYRIDIN 2 YLETHYNYLPYRIDINE; METABOTROPIC RECEPTOR 5; PYRIDINE DERIVATIVE; RADIOLIGAND; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BRAIN; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISSOCIATION CONSTANT; FEMALE; FRAGILE X SYNDROME; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; MALE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; RECEPTOR DENSITY; RECEPTOR UPREGULATION; SCHOOL CHILD;

ANIMALIA;

EID: 84878004228     PISSN: None     EISSN: 20402392     Source Type: Journal    
DOI: 10.1186/2040-2392-4-15     Document Type: Article

References (26)

1. Fragile X-associated disorders: a clinical overview. Gallagher A, Hallahan B, J Neurol 2012 259 401 413 10.1007/s00415-011-6161-3 21748281
2. Fragile X mental retardation protein: past, present and future. Kim M, Ceman S, Curr Protein Pept Sci 2012 13 358 371 10.2174/138920312801619420 22708486
3. Absence of expression of the FMR-1 gene in fragile X syndrome. Pieretti M, Zhang FP, Fu YH, Warren ST, Oostra BA, Caskey CT, Nelson DL, Cell 1991 66 817 822 10.1016/0092-8674(91)90125-I 1878973 (Pubitemid 121001715)
4. The fragile X mental retardation protein inhibits translation via interacting with mRNA. Li Z, Zhang Y, Ku L, Wilkinson KD, Warren ST, Feng Y, Nucleic Acids Res 2001 29 2276 2283 10.1093/nar/29.11.2276 11376146 (Pubitemid 32514930)
5. Therapeutic strategies in fragile X syndrome: dysregulated mGluR signaling and beyond. Gross C, Berry-Kravis EM, Bassell GJ, Neuropsychopharmacology 2012 37 178 195 10.1038/npp.2011.137 21796106
6. The mGluR theory of fragile X mental retardation. Bear MF, Huber KM, Warren ST, Trends Neurosci 2004 27 370 377 10.1016/j.tins.2004.04.009 15219735 (Pubitemid 38829251)
7. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Huber KM, Gallagher SM, Warren ST, Bear MF, Proc Natl Acad Sci USA 2002 99 7746 7750 10.1073/pnas.122205699 12032354 (Pubitemid 34568762)
8. Correction of fragile X syndrome in mice. Dolen G, Osterweil E, Rao BS, Smith GB, Auerbach BD, Chattarji S, Bear MF, Neuron 2007 56 955 962 10.1016/j.neuron.2007.12.001 18093519 (Pubitemid 350251119)
9. Suppression of two major fragile X syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Yan QJ, Rammal M, Tranfaglia M, Bauchwitz RP, Neuropharmacology 2005 49 1053 1066 10.1016/j.neuropharm.2005.06.004 16054174 (Pubitemid 41503304)
10. In vitro receptor binding assays: general methods and considerations. Bigott-Hennkens HM, Dannoon S, Lewis MR, Jurisson SS, Q J Nucl Med Mol Imaging 2008 52 245 253 18475249
11. Radioligand binding methods for membrane preparations and intact cells. Bylund DB, Toews ML, Methods Mol Biol 2011 746 135 164 10.1007/978-1-61779-126- 0-8 21607856
12. Analyzing Data with GraphPad Prism, http://graphpad.com/manuals/ analyzingdata.pdf
13. Dysregulation of fragile X mental retardation protein and metabotropic glutamate receptor 5 in superior frontal cortex of individuals with autism: a postmortem brain study. Fatemi SH, Folsom TD, Mol Autism 2011 2 6 10.1186/2040-2392-2-6 21548960
14. FMR1 premutation and full mutation molecular mechanisms related to autism. Hagerman R, Au J, Hagerman P, J Neurodev Disord 2011 3 211 224 10.1007/s11689-011-9084-5 21617890
15. Fragile X and autism: intertwined at the molecular level leading to targeted treatments. Hagerman R, Hoem G, Hagerman P, Mol Autism 2010 1 12 10.1186/2040-2392-1-12 20858229
16. A reduced number of metabotropic glutamate subtype 5 receptors are associated with constitutive homer proteins in a mouse model of fragile X syndrome. Giuffrida R, Musumeci S, D'Antoni S, Bonaccorso CM, Giuffrida-Stella AM, Oostra BA, Catania MV, J Neurosci 2005 25 8908 8916 10.1523/JNEUROSCI.0932- 05.2005 16192381 (Pubitemid 41384459)
17. Down regulation of mGluR-dependent gabaergic signaling in fragile X syndrome. Govindaiah G, Venkitaramini DV, Chaki S, Cox CL, Proceedings: Neuroscience 2011 Washington, DC: Society for Neuroscience 2011 774.06/P4
18. Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Brown V, Jin P, Ceman S, Darnell JC, O'Donnell WT, Tenenbaum SA, Jin X, Feng Y, Wilkinson KD, Keene JD, Darnell RB, Warren ST, Cell 2001 107 477 487 10.1016/S0092-8674(01)00568-2 11719188 (Pubitemid 33152783)
19. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. Berry-Kravis E, Hessl D, Coffey S, Hervey C, Schneider A, Yuhas J, Hutchison J, Snape M, Tranfaglia M, Nguyen DV, Hagerman R, J Med Genet 2009 46 266 271 10.1136/jmg.2008.063701 19126569
20. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Jacquemont S, des Portes V, Curie A, Torrioli MG, Berry-Kravis E, Hagerman RJ, Ramos FJ, Cornish K, He Y, Paulding C, Neri G, Chen F, Hadjikhani N, Martinet D, Meyer J, Beckmann JS, Delange K, Brun A, Bussy G, Gasparini F, Hilse T, Floesser A, Branson J, Bilbe G, Johns D, Gomez-Mancilla B, Sci Transl Med 2011 3 64ra61
21. Advances in the treatment of fragile X syndrome. Hagerman RJ, Berry-Kravis E, Kaufmann WE, Ono MY, Tartaglia N, Lachiewicz A, Kronk R, Delahunty C, Hessl D, Visootsak J, Picker J, Gane L, Tranfaglia M, Pediatrics 2009 123 378 390 10.1542/peds.2008-0317 19117905
22. GRM 5 in the caudate nucleus in schizophrenia. Ghose S, Gleason K, Potts B, Lewis K, Tamminga C, Proceedings: Neuroscience 2009 Chicago, IL: Society for Neuroscience 2009 340.3/N24
23. Sam68 sequestration and partial loss of function are associated with splicing alterations in FXTAS patients. Sellier C, Rau F, Liu Y, Tassone F, Hukema RK, Gattoni R, Schneider A, Richard S, Willemsen R, Elliott DJ, Hagerman PJ, Charlet-Berguerand N, EMBO J 2010 29 1248 1261 10.1038/emboj.2010.21 20186122
24. RNA-binding proteins hnRNP A2/B1 and CUGBP1 suppress fragile X CGG premutation repeat-induced neurodegeneration in a Drosophila model of FXTAS. Sofola OA, Jin P, Qin Y, Duan R, Liu H, De Haroch M, Nelson DL, Botas J, Neuron 2007 55 565 571 10.1016/j.neuron.2007.07.021 17698010 (Pubitemid 47223640)
25. Human PET studies of metabotropic glutamate receptor subtype 5 with 11C-ABP688. Ametamey SM, Treyer V, Streffer J, Wyss MT, Schmidt M, Blagoev M, Hintermann S, Auberson Y, Gasparini F, Fischer UC, Buck A, J Nucl Med 2007 48 247 252 17268022 (Pubitemid 47555351)
26. Metabotropic glutamate subtype 5 receptors are quantified in the human brain with a novel radioligand for PET. Brown AK, Kimura Y, Zoghbi SS, Simeon FG, Liow JS, Kreisl WC, Taku A, Fujita M, Pike VW, Innis RB, J Nucl Med 2008 49 2042 2048 10.2967/jnumed.108.056291 19038998